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Serum IgE Autoantibodies Target Keratinocytes in
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Sabine Altrichter1, Ernst Kriehuber1,2, Julia Moser1, Rudolf Valenta3, Tamara Kopp1 and Georg Stingl1
Previous studies have shown that sera of patients with severe atopic dermatitis (AD) contain IgE specific for self-
proteins, supporting the hypothesis of autoreactivity as a pathogenic factor in AD. In this study, we screened a
large panel of AD patients (n¼ 192) by western blotting (WB) for IgE reactivity not only against the human
epithelial cell line A431 but also against primary keratinocytes (KCs). To investigate autoantigenic cell structures
in detail, normal human skin and primary KCs were incubated with sera from both WB-reactive patients and, for
control purposes, healthy individuals, and analyzed by immunohistology, confocal laser microscopy, and flow
cytometry. Our analysis revealed that 28% of AD patients, but not healthy individuals, display serum IgE
autoreactivity by WB analysis. The individual IgE reaction patterns of the sera pointed to the existence of unique
as well as common specificities against epidermal or A431-derived proteins. Immunostainings identified
cytoplasmic and, occasionally, also cell membrane-associated moieties as targets for autoreactive IgE antibodies.
Interestingly, in certain autoreactive patients, the surface-staining pattern was accentuated at cellular contact
sites. We conclude that IgE autoreactivity is common, particularly among severe AD patients, and that non-
transformed primary cells are needed for characterization of the entire spectrum of IgE-defined autoantigens.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic relapsing inflammatory
skin disease occurring in 5–20% of children and 1–3% of
adults. Allergen studies indicate that approximately 80% of
AD patients have elevated levels of total and exoallergen-
specific IgE, which is directly associated with the severity of
disease (Tan et al., 1996). Moreover, there exists a small
proportion of patients with the typical signs of AD in which
sensitization to a broad panel of exoallergens is not
detectable by in vitro or in vivo tests (Schmid-Grendelmeier
et al., 2001). This finding supports the involvement of either a
non-immunological or an autoreactive pathomechanism in
the perpetuation of the clinical manifestations.
In fact, in the past decade autoreactive IgE antibodies
against self-proteins have been identified in AD (Valenta et al.,
1996; Natter et al., 1998; Fluckiger et al., 2002). Studies
concerning endogenous antigens as triggers in AD have shown
that sera from atopic patients, particularly those from patients
with severe AD, contain IgE antibodies against human proteins
expressed in histogenetically different cell types, most
importantly in epithelial cells (Valenta et al., 1996; Natter
et al., 1998; Seiberler et al., 1999a, b). Some of the IgE-defined
epithelial autoantigens (for example, Hom s 1–5) have been
identified and characterized at the molecular level (Mossabeb
et al., 2002). These autoantigens are intracellular, mostly
cytoplasmic proteins (Natter et al., 1998), suggesting that their
release from damaged tissue would trigger responses mediated
by IgE or T cells (Valenta et al., 1998) in AD patients.
Recombinant human autoallergens characterized so far
result from immunoscreenings of an epithelial carcinoma cell
line (A431) (Seiberler et al., 1999a, b), which may not
perfectly reflect the physiological repertoire of proteins
expressed in the epidermis. Skin-derived autoantigens poten-
tially relevant for the disease could thus have been over-
looked. Therefore, we wanted to analyze the range of IgE
autoreactivities against primary epidermal cell-derived pro-
teins and to compare them with those against A431-derived
proteins. Furthermore, we wished to discover against which
cell type, subcellular structure, or non-cellular formations of
the skin the IgE-autoantibodies were directed. By doing so,
we sought to build a basis for future investigations of their
molecular nature.
RESULTS
Serum IgE autoreactivity is present in one fourth of AD patients
In a first set of experiments, we analyzed the prevalence of
epithelial cell-reactive serum IgE autoantibodies in a large
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study population of AD patients. A total of 192 patient sera
were screened by western blotting (WB) with protein extracts
derived from the epithelial cell line A431 and with epidermal
extracts from the skin of one healthy donor. A serum was
considered ‘‘autoreactive’’ if the IgE contained in it recog-
nized at least one band in one of the protein extracts used.
Healthy individuals completely lacked serum IgE reactivity
against the above-mentioned protein extracts, whereas
approximately one-fourth (28%, n¼54) of all AD patients
exhibited IgE reactivity against both epithelial extracts
(Figure 1). IgE autoreactivity against proteins derived
from normal dermis was absent in all tested sera (data not
shown), probably due to the cellular paucity of this tissue.
IgE autoreactivity against primary epidermal extracts was
irrespective of the healthy skin donor, indicating ubiqui-
tous occurrence of autoantigens in healthy human skin.
(Figure S1).
IgE autoreactivity against epidermis-derived proteins is clearly
associated with elevated total serum IgE and the severity of
disease
Next, we set out to identify common clinical features of
autoreactive AD patients. Statistical analysis of the clinical
data revealed that autoreactive AD patients exhibit signifi-
cantly (Po0.001) higher total serum IgE levels when
compared with non-autoreactive AD patients. Despite this
significant correlation between IgE autoreactivity and high
total serum IgE levels (41,000 IUml1), there also existed
several AD patients with elevated serum IgE levels
(o1,000 IUml1) who did not show autoreactivity against
epithelial proteins. These patients provide an internal control
and indicate that IgE autoreactivity does not occur as a non-
specific phenomenon due to high IgE levels.
Disease activity, as determined by the Investigators’
Global Assessment (IGA) Score and the Eczema Area and
Severity Index (EASI), was also significantly (Po0.001) higher
in autoreactive patients than in non-autoreactive ones
(Figure 2). These data are in agreement with earlier
observations showing that AD patients with serum IgE
autoreactivity form a distinct subpopulation of patients with
severe disease and considerably higher total serum IgE
(Natter et al., 1998). In contrast to this observation, we were
not able to find a significant correlation within the group of
autoreactive AD patients between the intensity of the WB
reaction or a special recognized moiety on the one hand and
the EASI and IGA on the other (data not shown), indicating
that IgE autoreactivity is an important but not the only
relevant factor in this complex skin disease.
Interestingly, all of the IgE-autoreactive patients met the
criteria of the extrinsic-type AD (that is, increased serum IgE
and/or sensitization to environmental allergens; Wollenberg
et al., 2000), whereas in the group of the non-autoreactive
AD patients 17% had a characteristic intrinsic-type AD
(Schmid-Grendelmeier et al., 2001; Novak and Bieber,
2003).
Comparison of the reactivity against epidermal protein extracts
and A431 extracts
To investigate which protein extract is best suited for the
detection of autoreactivity in AD patients, we compared
reactivity against A431 with that against proteins extracted
from freshly isolated keratinocytes (KCs) by WB. Of the 54
patients with IgE autoantibodies, 45 (¼83%) recognized
primary epidermis-derived proteins and 42 (¼ 78%) recog-
nized A431-derived proteins. Although most AD sera (61%)
reacted with antigens in both the extracts (Table 1), 12 AD
patients (¼ 22%) reacted exclusively with extracts from
epidermal tissue and nine (¼17%) exclusively with A431
extracts. These data indicate that potentially autoreactive
patients could have been overlooked if the screening was
solely performed with protein extracts derived from the cell
line A431 and that a maximum detection can be achieved by
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Figure 1. Representative WB with sera of AD patients and healthy controls. Protein extracts of primary human epidermis or the epithelial cell line A431
were separated by SDS–PAGE, blotted onto nitrocellulose-membranes, cut into strips, blocked, and incubated with individual sera of patients (AD1–13)
or healthy control individuals (C1–5); serum IgE reactivity was detected using HRP-conjugated mouse anti-human IgE mAb.
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a combination of both protein extracts. There was no
difference in the clinical scores and the IgE levels within
the autoreactive AD patients detected by the two distinct
antigenic sources (Table 1).
A detailed analysis of the band pattern in the western blots
revealed that the IgE-autoreactive moieties in epidermal
extracts differed in their molecular weights from those
identified in A431 extracts by the very same sera. When
analyzing interindividual serum reactivity against cell line
A431, we could not detect prevalently recognized moieties
among autoreactive AD patients. In contrast, when using
primary epidermal extracts as an antigenic source, we were
able to identify a common band of approximately 30 kDa in
60% of all autoreactive AD patients (Figure 1).
Autoantigens are expressed by KCs in the skin
Next, we sought to determine which cells of the skin express
IgE-defined autoantigens. For this purpose, frozen sections
of normal human skin were incubated with the sera of
15 autoreactive AD patients or five healthy controls. Serum
IgE that bound to the sections was detected with an anti-IgE
antibody. We found that six of 15 patients, but none of the
healthy individuals, showed detectable IgE reactivity against
normal human epidermis. Figure 3 shows representative
examples of such reaction patterns. Similar to the results
obtained by WB, we detected an interindividually hetero-
geneous IgE-binding pattern. For example, serum IgE of AD
patient I showed predominantly nuclear labeling, whereas
that from patient II was preferentially bound to membrane-
associated structures. In total, two of the 15 AD patients had
clearly detectable serum IgE reactivity against the cell
periphery of KCs.
Next, primary undifferentiated KCs were incubated with
sera of the six AD patients, which had shown epidermal IgE
binding by immunohistology (IH), and sera of two healthy
controls. Using immunofluorescence microscopy, we were
able to confirm the results derived from IH and showed that
serum IgE binding is most pronounced at sites of cellular
contact in the two patients with IgE reactivity against
membrane structures (Figure 3). This indicates that junctional
structures may be targets for autoreactive IgE of certain
patients. Anti-IgE immunostainings of KCs incubated with
sera from healthy persons gave no detectable signal.
Autoantigens can occur on various subcellular structures of
KCs, including cell surface
To determine whether the serum IgE of our patients exhibiting
peripheral staining by immunofluorescence binds to extra-
cellular or intracellular membrane structures of KCs, we
performed FACS analysis with viable KCs that were
non-enzymatically detached and probed with autoreactive
AD serum. Surface-bound IgE was detected with mouse anti-
human IgE mAb and Alexa488-labeled goat anti-mouse
IgG antibody (Ab). Using this method, we found serum
IgE binding to detached viable primary KCs in three of
15 autoreactive AD patients (Figure S2). This binding of
the autoreactive IgE in the three AD sera was almost com-
pletely prevented when the KCs were trypsin-treated before
incubation with patient sera (data not shown), demonstrating
that freely accessible surface proteins are the targets of
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Figure 2. Box plot of serum autoreactivity and total serum IgE, IGA score, and EASI score. Autoreactive and non-reactive AD patients were correlated with
the total serum IgE and clinical scores IGA and EASI. The black bar indicates the median score or IgE level; the margins of the colored boxes indicate the
25th and 75th percentile; the whiskers indicate 1.5 interquartile distance; and the open circles show mavericks (outside 1.5 interquartile distance). All
three statistical analyses revealed Po0.001 as defined by the Mann–Whitney-U-test and are thus statistically significant.
Table 1. Statistical analysis of the autoreactive AD patients
Autoreactivity against
% of autoreactive
AD patients (n=54)
Number of tested
persons (n)
Intrinsic type
of AD (n)
Mean serum
IgE (IUml1) (SD)
Mean IGA
(SD)
Mean EASI
(SD)
A431 and epidermis 61 33 0 1,788* (±463.6) 3.4* (±1.2) 22.2* (±17.2)
A431 alone 17 9 0 1,551* (±775.2) 3.5* (±1.4) 25.9* (±16.3)
Epidermis alone 22 12 0 1,265* (±710.2) 3.6* (±1.0) 28.9* (±9.5)
Non-autoreactive 0 138 23 681 (±835.2) 2.4 (±1.2) 10.0 (±10.6)
AD, atopic dermatitis; EASI, eczema area and severity index; IGA, Investigators’ Global Assessment score.
*No statistically significant differences between the three subgroups of AD patients.
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autoreactive serum IgE. Surface IgE binding was limited
to epithelial cells, with a significant preferential binding
to primary KCs, and could not be detected on other tumor
or primary cell types (Table S1), suggesting the recognition
of KC-specific autoantigens.
In a next step, we also performed immunostainings with
autoreactive sera on primary KCs cultured on slides (Figure 4).
By this method, we detected membrane labeling of the
viable cells in five of 15 autoreactive AD patients. Compared
with FACS analysis, two additional, but rather weak, KC
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Figure 3. IH and immunofluorescence stainings of tissue sections of normal skin and cultured primary KCs. WB: Protein extract of primary human epidermis
was separated by SDS–PAGE, blotted onto nitrocellulose-membranes, cut into strips, blocked, and incubated with individual sera of patients or healthy
control individuals; serum IgE reactivity was detected using HRP-conjugated mouse anti-human IgE mAb. IH: Original magnification  40. Frozen skin sections
of normal human skin were acetone-fixed and incubated with patient serum, and bound IgE was detected with mouse anti-human IgE-HRP mAb and AEC
reagent (red staining). Melanocytes are visible in the basal layer of the epidermis as brown cells. Immunofluorescence: Original magnification  100.
Primary human KCs were grown on chamber slides (low calcium, basal cell-like phenotype), fixed, incubated with patient serum, and washed, and cell-bound
IgE was detected with a self-labeled mouse anti-human IgE-A488 mAb (staining shown in green). The magnification is presented as scale bar within
each microscopic picture.
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Figure 4. Immunofluorescence stainings of viable cultured primary KCs. Original magnification  100: Primary human KCs were grown on chamber
slides (low calcium, basal cell-like phenotype)and incubated with patient serum or healthy control serum, and cell-bound IgE was detected with a mouse
anti-human IgE Ab followed by goat anti-mouse-A488 Abs. Propidium iodide was added during the first antibody-incubation step to visualize dead cells.
Finally, cells were fixed, permeabilized, and stained with rhodamine–phalloidin to enable visualization of the cytoskeleton of the KCs. The upper panel shows
IgE staining (green), and the lower one depicts the results of an IgE (green)/phalloidin staining (red) double staining. None of the cells exhibited nuclear
propidium iodide positivity. Serum IgE of patient II binds to the surface of KCs in a dotted manner, whereas in patient III IgE seems to bind more homogeneously
to the outer membrane. The magnification is presented as scale bar within each microscopic picture.
www.jidonline.org 2235
S Altrichter et al.
Autoreactivity in Atopic Dermatitis
surface–reactive AD patients were identified by immuno-
fluorescence, possibly due to the higher sensitivity of the
latter method.
DISCUSSION
Although serum IgE reactivity against human proteins had
been reported to occur in AD sera some 10 years ago
(Valenta et al., 1996), our knowledge about the significance
of this phenomenon is still incomplete. The recombinant
human autoallergens characterized so far (Hom s 1–5) result
from immunoscreenings of the epithelial carcinoma cell line
A431 with sera of autoreactive AD patients (Natter et al.,
1998). Results obtained previously show that IgE reactivity of
AD sera against these structures is a rather infrequent event
(Natter et al., 1998; Valenta et al., 1998; Mossabeb et al.,
2002; Aichberger et al., 2005). As the phenomenon of serum
IgE autoreactivity occurs in approximately a quarter of our
study population, Hom s 1–5 are likely to represent only
a small fraction of the target antigens recognized by
autoreactive IgE, suggesting that important autoreactive
targets still await identification.
To address this issue, we decided to use primary epidermal
cell extracts as a screening tool for IgE autoreactivity
and to compare the results with the previously used extracts
derived from A431. Our screening revealed that a consider-
able portion of AD patients (28%) exhibit serum IgE
autoreactivity against epidermal extracts and extracts from
the epithelial cell line A431. This autoreactivity in AD
patients was significantly correlated with the severity of the
disease, defined by the amount of total serum IgE and the
clinical scores on the EASI and IGA. This relationship
suggests that IgE autoantibodies are the result of repetitive
and severe injury of the skin. Thus, it is conceivable that
environmental exoallergens initiate the acute phase of the
allergic cutaneous disease (Valenta et al., 2000) and thereby
destruction of KCs and release of autoantigens into the
circulation. IgE autoimmunity may consequently contribute
to chronicity of the disease even in the absence of environ-
mental allergens. This hypothesis is supported by longitudinal
studies showing that IgE responses to autoallergens occa-
sionally increase during periods of disease exacerbation, and
by the discovery that some environmental allergens share
structural and functional similarities with human proteins
(Crameri et al., 1996; Meyer et al., 1999; Kinaciyan et al.,
2002).
Interestingly, all the autoreactive AD patients were of the
extrinsic type (total serum IgE4100 IUml1 and/or sensitiza-
tion against common allergens). Three autoreactive patients
displayed elevated total serum IgE but no sensitization against
common allergens. These patients may be sensitized to
exoallergens not tested by us, or, alternatively, the elevated
total serum IgE may result from a ‘‘pure’’ reactivity against
autoallergens. The latter explanation is in accordance with
a report of two intrinsic-type AD patients with IgE auto-
immunity against an exoallergen-crossreactive human
protein (Schmid-Grendelmeier et al., 2005).
An explanation for the significant correlation of auto-
reactivity and severity of the disease is that elevated
autoreactive serum IgE levels themselves account for the
worsening of disease. IgE immune complexes could target
effector cells like mast cells and basophils (Valenta et al.,
1996; Natter et al., 1998), initiating the release of pre-
formed mediators (that is, histamine, proteoglycans, tryptase,
chymase), the production of cytokines (that is, IL-4, IL-5,
IL-13), and, consequently, an allergic tissue response
(Irani et al., 1989). Support for this idea comes from the find-
ing that purified recombinant IgE autoantigens caused
histamine release from basophils and induced immediate
type-I skin reactions (Valenta et al., 1991, 1996; Crameri
et al., 1996; Natter et al., 1998; Appenzeller et al., 1999).
When we compared the moieties recognized in epidermal
extracts and extracts derived from A431, we found inco-
herent band patterns in most autoreactive patients, indicating
the presence of distinct autoantigens in the two protein
extracts. Based on these results, we propose that extracts of
freshly isolated skin cells reflect the in vivo antigen situation
better than the A431 tumor cell extracts, and are thus
indispensable for screening for autoreactive AD patients. In
addition, a substantial proportion of autoreactive AD patients
showed serum IgE reactivity selectively against proteins
derived from epidermal and not A431 extracts, suggesting
that autoreactive AD patients might have been overlooked
when the screening was performed solely with cell line A431.
We cannot definitely rule out the possibility that exogenous
microbial antigens or allergens deposited in the skin are also
recognized by serum IgE (Crameri et al., 1996; Schmid-
Grendelmeier et al., 2005). The fact that we detected IgE
serum reactivity against several sterile epidermal cell line
preparations (A431, HeLa) and normal epidermal extracts
strongly suggests that IgE autoreactivity is a major component
of the IgE self-reactivity observed.
The comparative analysis of the moieties recognized
revealed that every patient’s serum IgE was directed against
an individual, very diverse spectrum of proteins in the
respective extracts. This diverse reaction pattern may explain
the low prevalence of serum IgE reactivity against the known
autoantigens (Hom s). Interestingly enough, and unlike the
situation with A431 extracts, we were able to identify a
presumably commonly recognized moiety at around 30 kDa
in extracts derived from epidermal sheets. Such a common
target protein is of great interest, as more ubiquitous proteins
are needed to analyze the pathogenetic relevance of these
IgE-defined autoantigens.
To determine against which structures of the skin the
serum IgE antibodies of the autoreactive patients are directed,
we performed IH stainings of normal human skin sections
that had been incubated with autoreactive serum IgE of
AD patients. We found an individually variable staining
pattern reaching from a predominant nuclear labeling
throughout the whole epidermis to a specific labeling of
the membranes of the basal layer cells. Flow cytometry
and cytological analysis of viable cultured KCs revealed
that the latter results from the staining of KC surfaces. Thus,
the reported intracellular localization of autoantigens in
AD (Crameri et al., 1996; Valenta et al., 1998; Fluckiger
et al., 2002) is not an obligatory feature. Moreover,
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cytological analysis of cultured KCs revealed diverse forms of
surface reactivity, indicating the existence of a variety of
surface-reactive target molecules for IgE in the individual
patients. It is particularly tempting to speculate that recogni-
tion of surface structures on KCs by serum IgE could result in
a direct crosstalk between IgE and epidermal KCs, leading to
perturbation and functional modulation of KC, similar to
what has been described for IgG autoantibodies in diseases
such as pemphigus vulgaris. In AD it is thus conceivable
that autoreactive IgE antibodies are directly responsible for
epidermal spongiosis.
It is also conceivable that KC surface-bound IgE facilitates
contact formation with FceRIþ positive cells, such as LCs or
IDECs (Stary et al., 2005). This direct interaction may lead to
enhanced antigen transfer from KCs to antigen-presenting
cells, and, as a consequence, to IgE-facilitated autoantigen
presentation (Maurer et al., 1998; Stary et al., 2005), which
may contribute to the chronicity of the disease (Mittermann
et al., 2004).
The frequent occurrence of IgE autoimmunity and its
strong correlation with severity of the disease suggests a
pathophysiologically important role of these autoantibodies
in AD, although we cannot definitively exclude the possibi-
lity that they occur as a ‘‘bystander’’ phenomenon (Mitter-
mann et al., 2004). However, approximately a quarter of the
AD patients exhibit serum IgE autoreactivity and the
detection of autoreactive serum IgE is a useful serological
marker for the disease activity in these patients. It defines a
new subgroup of AD patients who may benefit from a
treatment with an anti-IgE mAb (Lane et al., 2006) and,
perhaps, from a specific immunotherapy. In this context, it
also seems imperative to subject such individuals to effective
antipruritic therapy, thus interrupting the vicious circle of
scratching, release of autoantigen, and, ultimately, develop-
ment of acute eczematous lesions. Such an intervention
should probably be implemented early in the patient’s life
(Mothes et al., 2005).
MATERIALS AND METHODS
Patients
We collected sera from 192 AD patients who had been diagnosed
according to the criteria of Hanifin and Rajka (1980). All individuals
were tested for their total serum IgE level and allergen-specific serum
IgE to common inhalant allergens, including grass pollen, birch
pollen, ragweed, house dust mites, cats, dogs, and molds (Immuno-
CAP system; Pharmacia, Uppsala, Sweden). Additionally, they were
scored on the IGA, the EASI, and other clinical instruments (Hanifin
et al., 2001; Eichenfield et al., 2005). Table S2 gives an overview of
the age, sex, mean total serum IgE, mean IGA, and mean EASI of the
patients tested. All patients ceased atopy-specific therapy, such as
steroids, topical calcineurin inhibitors, and antihistamines, at least
2 weeks before enrollment. Sera of non-allergic volunteers (n¼ 26),
without allergic personal history, served as controls. Sera were
stored at –20 1C until investigation.
Tissue specimens
Whole skin: frozen tissue sections from normal adult human skin
were purchased from BioChain (Hayward, CA).
Epidermal sheets and dermis: normal adult human skin from non-
atopic individuals was obtained ex vivo from reduction surgery and
split-thickness samples were prepared with a manual dermatome.
Epidermal sheets were separated from the dermis after 1-hour
dispase (Becton Dickinson, Franklin Lakes, NJ) digestion of the
basement membrane as described previously (Kriehuber et al.,
2001).
Cell lines
The human epithelial cell line A431 was obtained from the
American Type Culture Collection (ATCC, Rockville, MD). Cells
were grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA)
supplemented with 2mM L-glutamine, 100Uml1 penicillin,
100mgml1 streptomycin, and 10% fetal calf serum (heat-
inactivated) at 37 1C, under 5% CO2, in a humidified incubator.
Primary human foreskin KCs were purchased from PromoCell
(Heidelberg, Germany) and grown in EpiLife medium (Cascade
Biologics, Portland, OR) supplemented with 0.006mM Ca2þ .
Western blot
Cultured cells (A431) and freshly isolated epidermal and dermal
sheets were dissolved in 2 reducing La¨mmli buffer (120mM
Tris pH 6.8, 4% SDS, 20% glycerol, 2.5% b-mercaptoethanol) by
sonication on ice. The protein extracts were cleared by high-speed
centrifugation, boiled for 5minutes at 96 1C, and stored at –20 1C
until use.
WB was performed as described previously (Kriehuber et al.,
2001). Briefly, proteins were separated by 12% SDS–PAGE,
transferred by semi-dry electroblotting onto nitrocellulose
membranes (0.2 mm; Biorad, Hercules, CA), and blocked with 5%
dry milk (blocking grade; Biorad)/phosphate-buffered saline (PBS).
The blots were then incubated with serum (1:5 diluted in blocking
milk) at 4 1C for at least 12 hours and washed with PBS-T
(PBSþ 0.1% Tween 20; Biorad). Binding of serum IgE was detected
using the anti-human IgE mAb B3102E8 (horseradish peroxidase
(HRP)-conjugated; Southern Biotechnology, Birmingham, AL)
(1:1,000). The immune reaction was visualized with ECL or
ECL-plus (Amersham Biosciences, Piscataway, NJ) according to the
manufacturer’s directions.
Immunohistochemistry
Frozen sections of normal human skin were acetone-fixed, chloro-
form-treated, rehydrated in PBS, blocked in 2% BSA/PBS, and
exposed to serum overnight at 4 1C. Afterward, bound IgE was
detected with anti-human IgE mAb B3102E8 (HRP-conjugated;
Southern Biotechnology) (1:200) and visualized with AEC reagent
(3-amino-9-ethylcarbazole; Sigma-Aldrich, St Louis, MO) according
to the manufacturer’s directions.
Immunofluorescence
Cytological analysis: culture slides. Primary KCs were grown
on culture slides (Becton Dickinson) until 70% confluence, fixed
with ice-cold acetone, blocked with 1% BSA/PBSþ 1% normal
mouse serum (DakoCytomation, Glostrup, Denmark), and incubated
with patient serum (1:5) for 1 hour on ice. After being washed with
PBS buffer, bound IgE was detected with A488-labeled (mAb
labeling kit; Invitrogen) mouse anti-human IgE-mAb B3102E8
(Southern Biotechnology). Slides were examined with a confocal
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microscope (LSM510; Carl Zeiss MicroImaging GmbH, Jena,
Germany).
Cytological analysis: culture slides of living KCs. Primary KCs
were grown on culture slides (Becton Dickinson) until 70%
confluence, blocked with 1% BSA/PBSþ 1% normal goat serum
(DakoCytomation), and incubated with patient serum (1:3) for 1 hour
on ice. After being washed with PBS buffer, bound IgE was detected
with mouse anti-human IgE-mAb B3102E8 (Southern Biotechnology)
and goat anti-mouse IgG A488 (Invitrogen). Propidium iodide (final
concentration, 1 mM; Invitrogen) was added to visualize dead cells.
Consequently, cells were fixed and permeabilized (cell permeabi-
lization kit; An der Grub, Kaumberg, Austria) according to the
manufacturer’s protocol and stained with rhodamine–phalloidin
(Molecular Probes, Eugene, OR). Slides were examined with a Zeiss
Axiophot fluorescent microscope and images were obtained from
areas where no propidium iodide-positive cells were visible by light
microscopy.
Statistics
Statistical analysis was performed using box-plot analysis and the
Mann–Whitney U-test (SPSS 12; SPSS Inc., Chicago, IL). P-values
o0.05 were considered statistically significant.
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